- Home
- TARS
as 07-05-2024 12:38pm EST
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 1.1B | IPO Year: | 2020 |
| Target Price: | $50.83 | AVG Volume (30 days): | 819.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.57 - $42.50 | Next Earning Date: | 08-08-2024 |
| Revenue: | $42,561,000 | Revenue Growth: | 53.22% |
| Revenue Growth (this year): | 733.61% | Revenue Growth (next year): | 82.78% |
Stock Insider Trading Activity of Tarsus Pharmaceuticals Inc. (TARS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Farrow Jeffrey S | TARS | See Remarks | Jun 17 '24 | Sell | $27.47 | 10,445 | $286,924.15 | 18,136 | SEC Form 4 |
| Wahl Bryan | TARS | General Counsel | Mar 15 '24 | Sell | $30.60 | 4,436 | $135,741.60 | 40,951 | SEC Form 4 |
| Whitfield Dianne C. | TARS | Chief Human Resources Officer | Mar 15 '24 | Sell | $30.60 | 4,314 | $132,008.40 | 34,181 | SEC Form 4 |
| Neervannan Seshadri | TARS | Chief Operating Officer | Mar 15 '24 | Sell | $30.60 | 4,879 | $149,297.40 | 64,767 | SEC Form 4 |
| Mottiwala Aziz | TARS | Chief Commercial Officer | Mar 15 '24 | Sell | $30.60 | 4,766 | $145,839.60 | 54,075 | SEC Form 4 |
| Azamian Bobak R. | TARS | President/CEO and Board Chair | Mar 15 '24 | Sell | $30.60 | 10,415 | $318,699.00 | 26,456 | SEC Form 4 |
| Azamian Bobak R. | TARS | President/CEO and Board Chair | Dec 27 '23 | Sell | $20.22 | 8,000 | $161,760.00 | 830,106 | SEC Form 4 |
| Trevejo Jose M. | TARS | CHIEF MEDICAL OFFICER | Dec 20 '23 | Sell | $20.00 | 2,252 | $45,040.00 | 2,251 | SEC Form 4 |
| Azamian Bobak R. | TARS | President/CEO and Board Chair | Dec 20 '23 | Sell | $19.96 | 9,443 | $188,482.28 | 868,663 | SEC Form 4 |
| Azamian Bobak R. | TARS | President/CEO and Board Chair | Dec 20 '23 | Sell | $20.36 | 30,557 | $622,140.52 | 838,106 | SEC Form 4 |
| Goldberg Andrew D. | TARS | Director | Dec 15 '23 | Buy | $18.96 | 1,000 | $18,960.00 | 3,000 | SEC Form 4 |
| Whitfield Dianne C. | TARS | Chief Human Resources Officer | Nov 29 '23 | Sell | $16.31 | 8,355 | $136,270.05 | 26,784 | SEC Form 4 |
| Wahl Bryan | TARS | General Counsel | Nov 29 '23 | Sell | $16.31 | 8,356 | $136,286.36 | 31,966 | SEC Form 4 |
| Azamian Bobak R. | TARS | President/CEO and Board Chair | Nov 15 '23 | Sell | $18.01 | 2,896 | $52,156.96 | 883,210 | SEC Form 4 |
| Azamian Bobak R. | TARS | President/CEO and Board Chair | Nov 15 '23 | Sell | $18.54 | 4,904 | $90,920.16 | 878,306 | SEC Form 4 |
| Azamian Bobak R. | TARS | President/CEO and Board Chair | Nov 15 '23 | Sell | $19.28 | 200 | $3,856.00 | 878,106 | SEC Form 4 |
Latest Tarsus Pharmaceuticals Inc. News
TARS Breaking Stock News: Dive into TARS Ticker-Specific Updates for Smart Investing
PR Newswire
25 days ago
NexTech Solutions Has Agreed to Acquire Rome Research Corporation to Expand Service Offerings and Enhance Mission Support Capabilities
Business Wire
25 days ago
Form 8.3 - Darktrace plc
Business Wire
25 days ago
Form 8.3 - International Distribution Services plc
Reuters
25 days ago
US Supreme Court rejects Kroger challenge to Grubhub trademark win
Investor's Business Daily
25 days ago
Dow Jones Falls As AMD Slides On Downgrade; Nvidia Stock Split Takes Effect
Business Wire
25 days ago
GoldATM Supports Growing Consumer Demand for Gold Purchase with New ATMs in North Carolina
GlobeNewswire
25 days ago
Middlefield Canadian Income PCC: Net Asset Value(s)
Business Wire
25 days ago
Form 8.3 - International Paper Company
Share on Social Networks:
Disclaimer
The information presented on this page, "TARS Tarsus Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.